The anticoagulant drug warfarin is a vitamin K antagonist, coumarin derivative which inhibits the synthesis of clotting factors II, VII, IX, and X, as well as the naturally occurring endogenous anticoagulant proteins C and S. Warfarin is still considered the mainstay of oral anticoagulant treatment, it is a difficult drug to manage due to its narrow therapeutic index. An inappropriate management of patients can lead to subtherapeutic or supratherapeutic levels, increasing the risk of thromboembolic episodes or hemorrhagic episodes, respectively. Common indications for the use of warfarin include stroke prevention in atrial fibrillation, preventing thrombus formation in patients with heart valves and treatment of venous thromboembolism. When warfarin therapy is initiated for venous thromboembolism, it should be given the first day, along with a heparin product or fondaparinux. The heparin product or fondaparinux should be continued for at least five days and until the patient's international normalized ratio is at least 2.0 for two consecutive days. The international normalized ratio goal and duration of treatment with warfarin vary depending on indication and risk. Warfarin therapy should be stopped five days before major surgery and restarted 12 to 24 hours postoperatively. Bridging with low-molecular-weight heparin or other agents is based on balancing the risk of throm boembolism with the risk of bleeding.
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ingestion. Plasma half life is 20-40 hours (36 hours average), duration of action: 2-6 days. It is metabolized in liver (microsomal enzymes depended) & excreted through urine, bile.
Warfarin acts by interfering in the interconversion of cyclic 2,3 vitamin K epoxide. The vitamin K epoxide reductase is inhibited by therapeutic doses of warfarin inhibiting thus the synthesis of vitamin K-dependent factors, leading to inhibition of -carboxylation of clotting factors II, VII, IV and X, and the anticoagulant proteins C and S. Effects on prothrombin time are produced in 24 to 36 hours after the initial dose and reach the maximum plasmatic concentration in 36 to 48 hours, maintained for 48 hours or more after discontinuance of dosing.
Clinical Management:
Although warfarin is still considered the mainstay of oral anticoagulant treatment, it is a difficult drug to manage due to its narrow therapeutic index, metabolism that is affected by many factors and numerous drug interactions. An inappropriate management of patients can lead to subtherapeutic or supratherapeutic levels, increasing the risk of 
Conclusion:
Since warfarin has a narrow therapeutic window and has been associated with many drug-drug and drugfood interactions, patient counseling is crucial. The evaluation revealed this as an area for improvement because opportunities for patient education were not always optimized. Initiation and management of warfarin therapy is often difficult.Guidelines have been developed to assist the clinician in determining target ranges for therapeutic success. In addition, strategies for rapid anticoagulation and management of supratherapeutic INR values are also described in the literature. Daily practice using these guidelines should make management of patients easier when warfarin therapy is required. * Patients who do not undergo PCI should be considered for 4 weeks triple therapy, after which clopidogrel should be stopped, and aspirin continued for a further 11 months (2C, Weak recommendation, low quality evidence).
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for warfarin should be carefully assessed for bleeding risk and discussed with their cardiologist, with a view to introducing warfarin and minimizing the duration of triple therapy (2C, Weak recommendation, low quality evidence).
* When combined warfarin and single antiplatelet agent are indicated, consideration should be given to use of aspirin given the higher bleeding risk associated with clopidogrel (2C, Weak recommendation, low quality evidence).
